Evidence map›Paper›PMID 31342260›Full record

ArticleSurgical endoscopy2020

Reduction of opioid use after implementation of enhanced recovery after bariatric surgery (ERABS).

Pearl Ma, Aaron Lloyd, Morgan McGrath, Riley Moore, Alice Jackson, Keith Boone, Kelvin Higa

Abstract read
PubMed Publisher
In one paragraph

Article in Surgical endoscopy, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
5.7field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 43 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Observational
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Pearl MaAdvanced Laparoscopic Surgery Associates, University of California San Francisco-Fresno, 205 E. River Park Circle #460, Fresno, CA, 93720, USA. Pearl.ma@gmail.com.ORCID 0000-0001-7267-1856
Aaron LloydFresno Heart and Surgical Hospital, Fresno, CA, USA.
Morgan McGrathFresno Heart and Surgical Hospital, Fresno, CA, USA.
Riley MooreFresno Heart and Surgical Hospital, Fresno, CA, USA.
Alice JacksonFresno Heart and Surgical Hospital, Fresno, CA, USA.
Keith BooneAdvanced Laparoscopic Surgery Associates, University of California San Francisco-Fresno, 205 E. River Park Circle #460, Fresno, CA, 93720, USA.
Kelvin HigaAdvanced Laparoscopic Surgery Associates, University of California San Francisco-Fresno, 205 E. River Park Circle #460, Fresno, CA, 93720, USA.
California State University, Fresno · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundEnhanced recovery after surgery (ERAS) protocols have been extensively proven in lower gastrointestinal surgery to decrease postoperative physiologic stress and length of stay (LOS). ERAS in bariatric surgery (ERABS) varies immensely from each program with inconsistent results with a predominant goal of reducing LOS. Our focus in implementing enhanced recovery after bariatric surgery (ERABS) protocols is aimed at reducing postoperative pain and opioid use.

methodsThis is a retrospective review of patients who underwent laparoscopic Roux-en-Y gastric bypass (RYGB) or sleeve gastrectomy (VSG) at a single high-volume center from June 2016 to October 2017. Patients on previous standard protocol were categorized into "Pre-Liposomal Bupivacaine (LB) group." After routine use of Exparel™, patients were grouped into "LB group." After ERABS protocol was initiated, patients were categorized into "ERABS/LB group." Postoperative opioids were converted to morphine equivalents units (MEU); pain scores, LOS, and 30-day outcomes were analyzed using combination of t test and Mann-Whitney U.

resultsA total of 1340 patients were included in the study: 304 patients in pre-LB group; 754 patients in LB group, and 282 patients in ERABS/LB group. Total hospital opioid use was 58.6 MEU in pre-LB, 40.8 MEU in LB, and 23.8 MEU in ERABS/LB (p = 0.01). ERABS/LB group found a 59.5% decline in MEU requirements compared to pre-LB (p < 0.001) and 44.9% of patients did not require any additional narcotics on the floor compared to 0% in pre-LB group (p < 0.001). ERABS/LB LOS was an average of 1.48 days compared to 1.54 days in pre-LB group (p = 0.03) with an overall decrease of 3.74% in readmission rates (p = 0.03).

conclusionsImplementation of ERABS significantly reduced postoperative opioid use, LOS, and readmissions. With ERABS, a more profound effect was observed than simply adding Exparel™ to preexisting protocols. Almost half of these patients did not require narcotics while recovering on the surgical floor. More studies are required to assess the true effect of ERABS without use of Exparel™.

Indexed as

Enhanced Recovery After SurgeryAdultAnalgesics, OpioidBariatric SurgeryFemaleHumansMaleMiddle AgedObesity, MorbidOpioid-Related DisordersRetrospective StudiesAnalgesics, OpioidBariatric surgeryEnhanced recoveryExparelLiposomal bupivacaineOpioidPostoperative pain

Identifiers

PMID31342260
OpenAlexW2963955122

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.